Pr Sylvain Ladoire
- Spécialité
- Oncologue médical, expert sein et urologie
- Hôpital
- Centre Georges-François Leclerc (Dijon)
- Derniers articles
-
- Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP). (10 févr. 2025)
- Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption. (7 févr. 2025)
- Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib. (1 févr. 2025)
- The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma. (2 janv. 2025)
- Real-world prevalence, treatment and survival of "high risk" early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry. (1 déc. 2024)